EZH2 and neoplasm: These inhibitors attenuated tumor growth, with AZD2014 exerting the most significant effects (Supplementary Fig. 5c, d) and also reduced mTORC1 activation (as assessed by EIF4EBP1 phosphorylation) and the expression of EZH2 and SUZ12 proteins (Fig. 4d, e).